肺がん診断の世界市場、市場規模、予測（2024年～2030年）、産業動向、シェア、成長、考察、インフレの影響、企業分析

世界の肺がん診断の市場規模は、2030年までに約308億4,000万米ドルに達すると予測されています。現代の医療において、肺がん診断は早期発見と個別化治療において極めて重要です。CTスキャンやMRIのような先進の画像診断戦略は、腫瘍や転移の特定を可能にし、病期分類や治療計画を支援します。遺伝子変異やタンパク質発現解析を含むバイオマーカー検査によって、患者に合わせた治療が可能になり、治療結果が改善され、副作用が最小限に抑えられます。さらに、リキッドバイオプシーは、非侵襲的に疾患の進行と治療反応を追跡することができます。技術と研究の絶え間ない改良により、肺がん診断は適合し続け、生存率と生活水準の向上が望めるようになっています。

世界の肺がん診断の市場規模は、予測期間（2024年～2030年）にCAGRで7.23%の成長が見込まれます。

世界の肺がん罹患率の上昇により、優れた肺がん診断への需要が高まっています。Lung Cancer Research Foundationによると、喫煙は肺がんの圧倒的なリスク要素であり、肺がんによる死亡の80％を占めます。一方、喫煙経験のない人が肺がんによる死亡者の残りの20％を占めています。早期発見技術は、画像技術やバイオマーカー検査を含め、患者の転帰を向上させます。世界の肺がん診断市場は、医療システムが検診プログラムと診断機器へのアクセスを優先するため、予測外に拡大しています。研究、進歩する技術、カスタマイズされた治療アプローチへの投資の増加は、蔓延する疾患への対処の増加を促進します。

マルチモーダル診断法の採用は、世界の肺がん診断市場に革命をもたらしています。臨床医は、CT、PET、MRIのような多様な画像診断モダリティを分子生物学的/遺伝子学的分析とともに統合することで、腫瘍の特徴や病期分類に関する幅広い知見を得ています。このアプローチは予後と治療計画の精度を補完し、がん診断市場の成長を促進しています。早期発見と個別化医薬品の重要性が認識されるにつれ、マルチモーダル診断ソリューションの需要は増加の一途をたどっており、肺がん診断の世界の情勢を形成しています。したがって、2023年の世界の肺がん診断の市場規模は189億2,000万米ドルとなりました。

北米の肺がん診断市場は大幅に拡大しています。これは、新技術の採用と弾力性のある医療インフラによって後押しされています。革新の道標として、卓越した診断の基準を設定し、世界の需要に拍車をかけています。さらに、特にがんの早期発見における、進行中の研究と改良活動が、肺がん診断およびスクリーニング市場を世界的に向上させることを約束し、世界中に蔓延するこの疾患の予防における極めて重要な役割を強化しています。

世界の肺がん診断市場でもっとも重要な分野の1つは画像検査です。

画像検査は世界の肺がん診断市場の最前線に位置します。これは、腫瘍の早期発見と正確な評価において極めて重要な機能を果たすためです。コンピューター断層撮影法（CT）、陽電子放射断層撮影法（PET）、磁気共鳴画像法（MRI）などの技術は、腫瘍の位置の特定、病期分類、治療計画の立案に役立つ肺組織の特定の可視化を提供します。その非侵襲性と早期段階で異常を発見する能力は、その認識に寄与しています。画像診断は、解像度と特異性を高める絶え間ない技術改良のおかげで、肺がん診断に不可欠となっています。このことが、世界市場の主要部門としての機能を確固たるものにしています。

非小細胞肺がんは世界の肺がん診断市場でもっとも重大な要素の1つです。

非小細胞肺がん（NSCLC）は、世界の肺がん診断市場で突出した地位を占めています。これは、罹患率が高く、多くの治療オプションがあるためです。NSCLCは、画像診断、バイオマーカーの評価、病理組織検査を含む診断の評価に対する需要を大きく促進しています。その異質な性質から、最高品質の治療法を選択するには正確な予後と病期分類が必要であり、診断技術の革新に拍車をかけています。さらに、特定のNSCLCサブタイプに合わせた中心的治療と免疫療法の進歩は、正しい診断の重要性をいっそう強く示しています。NSCLCは医療に大きな負担を与え続けているため、その診断段階は世界の肺がん診断市場の要であり続けています。

当レポートでは、世界の肺がん診断市場について調査し、市場の成長促進要因と課題や、セグメント、地域、企業の包括的な分析を提供しています。

目次

第1章 イントロダクション

第2章 調査と調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 成長促進要因
• 課題

第5章 世界の肺がん診断市場

第6章 市場シェア - 世界の肺がん診断の分析

• 診断検査タイプ別
• がんタイプ別
• エンドユーザー別
• 国別

第7章 診断検査タイプ - 世界の肺がん診断市場

• 画像検査
• 生検
• 喀痰細胞診
• 分子検査
• その他

第8章 がんタイプ - 世界の肺がん診断市場

• 非小細胞肺がん
• 小細胞肺がん

第9章 エンドユーザー - 世界の肺がん診断市場

• 病院関連研究所
• 独立診断研究所
• 画像診断センター
• がん研究機関
• その他

第10章 国 - 世界の肺がん診断市場

• 北米
  • 米国
  • カナダ
• 欧州
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • ベルギー
  • オランダ
  • トルコ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • タイ
  • マレーシア
  • インドネシア
  • オーストラリア
  • ニュージーランド
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 ポーターのファイブフォース分析 - 世界の肺がん診断市場

第12章 SWOT分析 - 世界の肺がん診断市場

第13章 企業分析 - 世界の肺がん診断市場

• llumina
• Abbott Laboratories
• Thermo Fisher Scientific, Inc
• QIAGEN N.V.
• Roche Holding AG.
• Sanofi S.A.
• Agilent Technologies
• bioMerieux

List of Figures

• Figure-01: Global - Lung Cancer Diagnostics Market (Billion US$), 2019 - 2023
• Figure-02: Global - Forecast for Lung Cancer Diagnostics Market (Billion US$), 2024 - 2030
• Figure-03: Diagnosis Test Type - Imaging Test Market (Million US$), 2019 - 2023
• Figure-04: Diagnosis Test Type - Forecast for Imaging Test Market (Million US$), 2024 - 2030
• Figure-05: Diagnosis Test Type - Biopsy Market (Million US$), 2019 - 2023
• Figure-06: Diagnosis Test Type - Forecast for Biopsy Market (Million US$), 2024 - 2030
• Figure-07: Diagnosis Test Type - Sputum Cytology Market (Million US$), 2019 - 2023
• Figure-08: Diagnosis Test Type - Forecast for Sputum Cytology Market (Million US$), 2024 - 2030
• Figure-09: Diagnosis Test Type - Molecular Test Market (Million US$), 2019 - 2023
• Figure-10: Diagnosis Test Type - Forecast for Molecular Test Market (Million US$), 2024 - 2030
• Figure-11: Diagnosis Test Type - Others Market (Million US$), 2019 - 2023
• Figure-12: Diagnosis Test Type - Forecast for Others Market (Million US$), 2024 - 2030
• Figure-13: Cancer Type - Non- Small Cell Lung Cancer Market (Million US$), 2019 - 2023
• Figure-14: Cancer Type - Forecast for Non- Small Cell Lung Cancer Market (Million US$), 2024 - 2030
• Figure-15: Cancer Type - Small Cell Lung Cancer Market (Million US$), 2019 - 2023
• Figure-16: Cancer Type - Forecast for Small Cell Lung Cancer Market (Million US$), 2024 - 2030
• Figure-17: End-User - Hospital Associated Labs Market (Million US$), 2019 - 2023
• Figure-18: End-User - Forecast for Hospital Associated Labs Market (Million US$), 2024 - 2030
• Figure-19: End-User - Independent Diagnostic Laboratories Market (Million US$), 2019 - 2023
• Figure-20: End-User - Forecast for Independent Diagnostic Laboratories Market (Million US$), 2024 - 2030
• Figure-21: End-User - Diagnostic Imaging Centers Market (Million US$), 2019 - 2023
• Figure-22: End-User - Forecast for Diagnostic Imaging Centers Market (Million US$), 2024 - 2030
• Figure-23: End-User - Cancer Research Institutes Market (Million US$), 2019 - 2023
• Figure-24: End-User - Forecast for Cancer Research Institutes Market (Million US$), 2024 - 2030
• Figure-25: End-User - Others Market (Million US$), 2019 - 2023
• Figure-26: End-User - Forecast for Others Market (Million US$), 2024 - 2030
• Figure-27: United States - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-28: United States - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-29: Canada - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-30: Canada - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-31: France - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-32: France - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-33: Germany - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-34: Germany - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-35: Italy - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-36: Italy - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-37: Spain - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-38: Spain - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-39: United Kingdom - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-40: United Kingdom - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-41: Belgium - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-42: Belgium - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-43: Netherlands - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-44: Netherlands - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-45: Turkey - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-46: Turkey - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-47: China - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-48: China - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-49: Japan - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-50: Japan - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-51: India - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-52: India - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-53: South Korea - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-54: South Korea - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-55: Thailand - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-56: Thailand - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-57: Malaysia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-58: Malaysia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-59: Indonesia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-60: Indonesia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-61: Australia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-62: Australia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-63: New Zealand - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-64: New Zealand - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-65: Brazil - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-66: Brazil - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-67: Mexico - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-68: Mexico - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-69: Argentina - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-70: Argentina - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-71: Saudi Arabia - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-72: Saudi Arabia - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-73: UAE - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-74: UAE - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-75: South Africa - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-76: South Africa - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-77: llumina - Lung Cancer Diagnostics Market (Million US$), 2019 - 2023
• Figure-78: llumina - Forecast for Lung Cancer Diagnostics Market (Million US$), 2024 - 2030
• Figure-79: Abbott Laboratories - Global Revenue (Million US$), 2019 - 2023
• Figure-80: Abbott Laboratories - Forecast for Global Revenue (Million US$), 2024 - 2030
• Figure-81: Thermo Fisher Scientific, Inc - Global Revenue (Million US$), 2019 - 2023
• Figure-82: Thermo Fisher Scientific, Inc - Forecast for Global Revenue (Million US$), 2024 - 2030
• Figure-83: QIAGEN N.V. - Global Revenue (Million US$), 2019 - 2023
• Figure-84: QIAGEN N.V. - Forecast for Global Revenue (Million US$), 2024 - 2030
• Figure-85: Roche Holding AG. - Global Revenue (Million US$), 2019 - 2023
• Figure-86: Roche Holding AG. - Forecast for Global Revenue (Million US$), 2024 - 2030
• Figure-87: Sanofi S.A. - Global Revenue (Million US$), 2019 - 2023
• Figure-88: Sanofi S.A. - Forecast for Global Revenue (Million US$), 2024 - 2030
• Figure-89: Agilent Technologies - Global Revenue (Million US$), 2019 - 2023
• Figure-90: Agilent Technologies - Forecast for Global Revenue (Million US$), 2024 - 2030
• Figure-91: bioMerieux - Global Revenue (Million US$), 2019 - 2023
• Figure-92: bioMerieux - Forecast for Global Revenue (Million US$), 2024 - 2030

List of Tables

• Table-01: Global - Lung Cancer Diagnostics Market Share by Diagnosis Test Type (Percent), 2019 - 2023
• Table-02: Global - Forecast for Lung Cancer Diagnostics Market Share by Diagnosis Test Type (Percent), 2024 - 2030
• Table-03: Global -Lung Cancer Diagnostics Market Share by Cancer Type (Percent), 2019 - 2023
• Table-04: Global - Forecast for Lung Cancer Diagnostics Market Share by Cancer Type (Percent), 2024 - 2030
• Table-05: Global - Lung Cancer Diagnostics Market Share by End-User (Percent), 2019 - 2023
• Table-06: Global - Forecast for Lung Cancer Diagnostics Market Share by End-User (Percent), 2024 - 2030
• Table-07: Global - Lung Cancer Diagnostics Market Share by Region (Percent), 2019 - 2023
• Table-08: Global - Forecast for Lung Cancer Diagnostics Market Share by Region (Percent), 2024 - 2030

Global Lung Cancer Diagnostics Market is predicted to be valued at around US$ 30.84 Billion by 2030, according to Renub Research. In modern-day healthcare, lung cancer diagnostics are pivotal in early detection and personalized treatment. Advanced imaging strategies like CT scans and MRI permit particular identification of tumors and metastases, assisting in staging and treatment planning. Biomarker testing, inclusive of genetic mutations and protein expression analysis, allows for centered remedies tailor-made to their patients, improving results and minimizing side effects. Further, liquid biopsies offer a non-invasive tracking of disease progression and remedy responses. With non-stop improvements in technology and research, lung cancer diagnostics continue to conform, offering a want for improved survival rates and standard of life.

Global Lung Cancer Diagnostics Market is predicted to increase at a CAGR of 7.23% during the projection period (2024 to 2030)

The demand for superior lung cancer diagnostics has improved because of the rising prevalence of the disease globally. According to the Lung Cancer Research Foundation, smoking is the dominating risk element for lung cancer, accounting for 80% of lung cancer deaths. In comparison, individuals who've in no way smoked account for the remaining 20% of lung cancer deaths. Early detection techniques enhance patient outcomes, including imaging technology and biomarker testing. The global lung cancer diagnostics market is expanding unexpectedly as healthcare systems prioritize screening programs and access to diagnostic equipment. Increased investments in studies, progressive technology, and customized remedy approaches fuel an increase in coping with prevailing diseases.

Adopting multimodal diagnostic procedures is revolutionizing the global lung cancer diagnostics market. Clinicians gain broad insights into tumor characteristics and staging by integrating diverse imaging modalities like CT, PET, and MRI alongside molecular and genetic analyses. This approach complements accuracy in prognosis and treatment planning, driving the growth of the cancer diagnostics market. With increasing recognition of the importance of early detection and personalized medicinal drugs, the demand for multimodal diagnostic solutions continues to push upward, shaping the landscape of lung cancer diagnostics worldwide. Hence, the global lung cancer diagnostics market was US$ 18.92 Billion in 2023.

The North America lung cancer diagnostic market has witnessed considerable expansion. This is fueled by adopting contemporary technology and a resilient healthcare infrastructure. As a beacon of innovation, it sets standards for diagnostic excellence, spurring worldwide demand. Moreover, ongoing studies and improvement endeavors, specifically in early cancer detection, promise to elevate the lung cancer diagnostic and screening market worldwide, reinforcing its pivotal role in preventing this pervasive sickness worldwide.

One of the most critical areas of the lung cancer diagnostics market worldwide is imaging tests

By diagnosis test type, the global lung cancer diagnostics market is fragmented into Imaging Tests, Biopsy, Sputum Cytology, Molecular Tests, and Others. Imaging tests stand among the forefront sections of the global lung cancer diagnostics market. This is due to their pivotal function in early detection and correct assessment of tumors. Technologies like computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) offer specified visualization of lung tissue, helping in tumor localization, staging, and remedy planning. Their non-invasive nature and capability to stumble on abnormalities at early phases contribute to their recognition. Imaging assessments are vital in lung cancer diagnosis, thanks to non-stop technological improvements that enhance resolution and specificity. This has solidified their function as a leading section in the worldwide market.

Non-Small Cell Lung Cancer is among the most significant elements in the global lung cancer diagnostics market

The global lung cancer diagnostics market is split by cancer type into non-small and small-cell lung cancer. Non-Small Cell Lung Cancer (NSCLC) holds one of the prominent positions in the global lung cancer diagnostics market. This is due to its high incidence and numerous treatment alternatives. NSCLC drives considerable demand for diagnostic assessments, which include imaging, biomarker evaluation, and histopathology. Its heterogeneous nature necessitates a precise prognosis and staging for top-quality remedy choice, spurring innovation in diagnostic technology. Moreover, advancements in centered treatments and immunotherapies tailor-made to particular NSCLC subtypes further underscore the importance of correct diagnosis. As NSCLC continues to pose a substantial healthcare burden, its diagnostic stage remains a cornerstone of the global lung cancer diagnostics market.

Hospital Associated Labs are integral to the global lung cancer diagnostics market

By end-user, the global lung cancer diagnostics market is categorized into Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others. Hospital Associated Labs is one of the most used in the global lung cancer diagnostics market. This is due to their accessibility and comprehensive services. Situated in healthcare centers, these labs offer short turnaround times for diagnostic tests, including imaging, biopsies, and molecular analyses. Their close collaboration with clinicians facilitates seamless patient care, making them a preferred choice for accurate and well-timed lung cancer analysis and treatment planning.

United States may continue to maintain its lead in the global market for lung cancer diagnostics

By country, the global lung cancer diagnostics market is divided into North America (United States, Canada), Europe (France, Germany, Italy, Spain, United Kingdom, Belgium, the Netherlands, and Turkey), Asia Pacific (China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, and New Zealand), Latin America (Brazil, Mexico, and Argentina), Middle East & Africa (South Africa, Saudi Arabia, and the UAE). The United States might stay dominant in the global lung cancer diagnostics market. This is pushed by the increasing occurrence of neurological disorders, contributing to improving the area's lung cancer diagnostics market.

For example, in line with a record by the American Society of Clinical Oncology (ASCO) in 2023, 81% of all lung cancer diagnoses in the United States were non-small cell lung cancers (NSCLC). Moreover, the United States has a sturdy healthcare system with advanced diagnostic tools, most lung cancer cases, and a focus on early detection and customized medication. It invests closely in R&D, propelling innovation and setting global lung cancer diagnosis standards.

Key Players

The global lung cancer diagnostics market comprises of leading companies like llumina, Abbott Laboratories, Thermo Fisher Scientific, Inc, QIAGEN N.V., Roche Holding AG., Sanofi S.A., Agilent Technologies, and bioMerieux.

In October 2023 - DELFI Diagnostics recently announced the launch of FirstLook Lung, a blood-based test that provides a new and more accessible way to detect lung cancer. This test offers a convenient, accurate, and personalized result by determining the likelihood of detecting lung cancer through low-dose CT (LDCT) with a negative predictive value (NPV) of 99.7 percent.

Diagnosis Test Type - Market breakup in 5 viewpoints:

1. Imaging Test

2. Biopsy

3. Sputum Cytology

4. Molecular Test

5. Others

Cancer Type - Market breakup in 2 viewpoints:

1. Non- Small Cell Lung Cancer

2. Small Cell Lung Cancer

End-User - Market breakup in 5 viewpoints:

1. Hospital Associated Labs

2. Independent Diagnostic Laboratories

3. Diagnostic Imaging Centers

4. Cancer Research Institutes

5. Others

Country - Market breakup in 25 Countries:

1. North America

• 1.1 United States
• 1.2 Canada

2. Europe

• 2.1 France
• 2.2 Germany
• 2.3 Italy
• 2.4 Spain
• 2.5 United Kingdom
• 2.6 Belgium
• 2.7 Netherlands
• 2.8 Turkey

3. Asia Pacific

• 3.1 China
• 3.2 Japan
• 3.3 India
• 3.4 South Korea
• 3.5 Thailand
• 3.6 Malaysia
• 3.7 Indonesia
• 3.8 Australia
• 3.9 New Zealand

4. Latin America

• 4.1 Brazil
• 4.2 Mexico
• 4.3 Argentina

5. Middle East & Africa

• 5.1 Saudi Arabia
• 5.2 UAE
• 5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. llumina

2. Abbott Laboratories

3. Thermo Fisher Scientific, Inc.

4. QIAGEN N.V.

5. Roche Holding AG.

6. Sanofi S.A.

7. Agilent Technologies

8. bioMerieux.

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Global Lung Cancer Diagnostics Market

6. Market Share - Global Lung Cancer Diagnostics Analysis

• 6.1 By Diagnosis Test Type
• 6.2 By Cancer Type
• 6.3 By EndUsers
• 6.4 By Country

7. Diagnosis Test Type - Global Lung Cancer Diagnostics Market

• 7.1 Imaging Test
• 7.2 Biopsy
• 7.3 Sputum Cytology
• 7.4 Molecular Test
• 7.5 Others

8. Cancer Type - Global Lung Cancer Diagnostics Market

• 8.1 Non- Small Cell Lung Cancer
• 8.2 Small Cell Lung Cancer

9. End-User - Global Lung Cancer Diagnostics Market

• 9.1 Hospital Associated Labs
• 9.2 Independent Diagnostic Laboratories
• 9.3 Diagnostic Imaging Centers
• 9.4 Cancer Research Institutes
• 9.5 Others

10. Country - Global Lung Cancer Diagnostics Market

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherlands
  • 10.2.8 Turkey
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Thailand
  • 10.3.6 Malaysia
  • 10.3.7 Indonesia
  • 10.3.8 Australia
  • 10.3.9 New Zealand
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 Middle East & Africa
  • 10.5.1 Saudi Arabia
  • 10.5.2 UAE
  • 10.5.3 South Africa

11. Porter's Five Analysis - Global Lung Cancer Diagnostics Market

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Rivalry
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis - Global Lung Cancer Diagnostics Market

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threat

13. Company Analysis - Global Lung Cancer Diagnostics Market

• 13.1 llumina
  • 13.1.1 Overviews
  • 13.1.2 Recent Development
  • 13.1.3 Revenues
• 13.2 Abbott Laboratories
  • 13.2.1 Overviews
  • 13.2.2 Recent Development
  • 13.2.3 Revenues
• 13.3 Thermo Fisher Scientific, Inc
  • 13.3.1 Overviews
  • 13.3.2 Recent Development
  • 13.3.3 Revenues
• 13.4 QIAGEN N.V.
  • 13.4.1 Overviews
  • 13.4.2 Recent Development
  • 13.4.3 Revenues
• 13.5 Roche Holding AG.
  • 13.5.1 Overviews
  • 13.5.2 Recent Development
  • 13.5.3 Revenues
• 13.6 Sanofi S.A.
  • 13.6.1 Overview
  • 13.6.2 Recent Development
  • 13.6.3 Financial Insights
• 13.7 Agilent Technologies
  • 13.7.1 Overview
  • 13.7.2 Recent Development
  • 13.7.3 Financial Insights
• 13.8 bioMerieux
  • 13.8.1 Overview
  • 13.8.2 Recent Development
  • 13.8.3 Financial Insights